Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Argus Health
Covington
Fuji
Accenture
AstraZeneca
UBS
Citi

Generated: December 15, 2018

DrugPatentWatch Database Preview

CUTIVATE Drug Profile

« Back to Dashboard

Which patents cover Cutivate, and when can generic versions of Cutivate launch?

Cutivate is a drug marketed by Fougera Pharms and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in fifteen countries.

The generic ingredient in CUTIVATE is fluticasone propionate. There are twenty-eight drug master file entries for this compound. Eighty-four suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Drug patent expirations by year for CUTIVATE
Pharmacology for CUTIVATE
Synonyms for CUTIVATE
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-14-yl propanoate
(6?,11?,16?,17?)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid fluoromethyl ester
(6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester
[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
474F142
6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate
80474-14-2
AB00513992
AB00513992_08
AB00513992-06
AB1010912
AC-457
AC1L9FLD
AJ-47435
AKOS015895220
AN-584/43505443
Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester
Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)-
ArmonAir RespiClick
ArmonAir RespiClickTM
Asmatil
atemur
Axotide
BC216013
BDBM50354849
BIF0710
BPBio1_001203
BR-72799
BRD-K62310379-001-03-0
Brethal
BSPBio_001093
C25H31F3O5S
CCG-100981
CCI 18781
CCI-18781
CHEBI:31441
CHEMBL1473
CS-1986
Cultivate
Cutivate (TN)
D01708
DB00588
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
Flixotide Disks
Flixotide Inhaler
Flonase
Flonase (TN)
Flonase Allergy Relief
Flonase Aq
Flovent
Flovent (TN)
Flovent Diskus
Flovent Diskus 100
Flovent Diskus 250
Flovent Diskus 50
Flovent HFA
Flovent-hfa
Fluinol
Flunase
Flusonal
Fluspiral
Fluticasone (propionate)
fluticasone 17-propionate
Fluticasone Impurity B
FLUTICASONE PROPIONATE
Fluticasone propionate (Flonase, Veramyst)
Fluticasone propionate (JAN/USAN)
Fluticasone propionate [USAN:USP]
Fluticasone propionate [USAN]
Fluticasone propionate for impurity C identification, EuropePharmacopoeia (EP) Reference Standard
Fluticasone propionate for impurity G identification, EuropePharmacopoeia (EP) Reference Standard
Fluticasone propionate, >=98% (HPLC), powder
Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard
Fluticasone Propionate, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Fluticasone propionate, United States Pharmacopeia (USP) Reference Standard
fluticasone proprionate
Fluticasonpropionat Allen
Flutide
Flutivate
Fluxonal
FN-25
FT-0082893
GTPL7080
HMS1571G15
HMS2051N19
HMS2098G15
HY-B0154
Inalacor
KS-1173
LS-19323
MFCD00866007
MLS001424085
MolPort-003-847-468
NC00231
NCGC00179308-01
NCGC00179308-05
O2GMZ0LF5W
Prestwick0_000997
Prestwick1_000997
Prestwick2_000997
Prestwick3_000997
Q-101393
Rinosone
RS0009
S-(Fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate
S-(fluoromethyl)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate,17-propionate
s1992
SBB071021
SC-19333
SCHEMBL4068
Skyron
SMR000469159
SPBio_002984
ST2407016
Trialona
Ubizol
UNII-O2GMZ0LF5W
WMWTYOKRWGGJOA-CENSZEJFSA-N
Xhance
ZINC3920027
Zoflut

US Patents and Regulatory Information for CUTIVATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms CUTIVATE fluticasone propionate CREAM;TOPICAL 019958-001 Dec 18, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fougera Pharms CUTIVATE fluticasone propionate OINTMENT;TOPICAL 019957-001 Dec 14, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fougera Pharms CUTIVATE fluticasone propionate LOTION;TOPICAL 021152-001 Mar 31, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Fougera Pharms CUTIVATE fluticasone propionate LOTION;TOPICAL 021152-001 Mar 31, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for CUTIVATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fougera Pharms CUTIVATE fluticasone propionate CREAM;TOPICAL 019958-001 Dec 18, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Fougera Pharms CUTIVATE fluticasone propionate OINTMENT;TOPICAL 019957-001 Dec 14, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CUTIVATE
Drugname Dosage Strength RLD Date
➤ Subscribe Lotion 0.05% ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for CUTIVATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0014 France ➤ Try a Free Trial PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
269 Luxembourg ➤ Try a Free Trial PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C/GB08/026 United Kingdom ➤ Try a Free Trial PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C0067 France ➤ Try a Free Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Argus Health
Covington
Fuji
Accenture
AstraZeneca
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.